Reduction in Spasms · chronic pain in MS
1 finding from 1 review
Quality of life · chronic back pain in MS
1 finding from 1 review
Reduction in pain intensity · chronic musculoskeletal pain in people with MS
1 finding from 1 review
Reduction in disability · chronic musculoskeletal pain in people with MS
1 finding from 1 review
Quality of life · chronic musculoskeletal pain in people with MS
1 finding from 1 review
Reduction in fatigue · chronic musculoskeletal pain in people with MS
1 finding from 1 review
Reduction in pain intensity · chronic neuropathic pain in MS
1 finding from 1 review
Reduction in fatigue · chronic neuropathic pain in MS
1 finding from 1 review
Rescue analgesia · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)
Ibuprofen taken pre-emptively (about 1 hour before treatment) showed no clear difference in rescue analgesia compared with ibuprofen taken post-treatment; GRADE not reported.
1 finding from 1 review
Dry mouth (xerostomia) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Bethanechol showed no clear difference in xerostomia (dry mouth, yes/no) compared with artificial saliva; GRADE not reported.
2 findings from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)
Analgesic (any: NSAID, paracetamol, local anaesthetic or opioid) probably leads to lower pain intensity (VAS 0-100 mm) compared with control (placebo or no treatment) (moderate certainty).
3 findings from 1 review
MD -11.66 [-16.15, -7.17]
10 studies · 685 participants
Moderate
MD -21.19 [-28.31, -14.06]
12 studies · 1012 participants
Moderate
MD -24.27 [-31.44, -17.11]
9 studies · 535 participants
Moderate
Salivary flow rate · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Salivary flow rate (unstimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Bethanechol led to higher salivary flow rate (unstimulated, ml/min) compared with artificial saliva; GRADE not reported.
2 findings from 1 review
Progression‐free survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Palifermin showed no clear difference in progression-free survival compared with placebo; GRADE not reported.
1 finding from 1 review
HR 1.06 [0.80, 1.42]
3 studies
GRADE not reported
Overall survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Bethanechol showed no clear difference in overall survival compared with artificial saliva; GRADE not reported.
1 finding from 1 review
Dysphagia (grade >= 3, 0-4 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine showed no clear difference in dysphagia (grade >= 3, 0-4 scale) compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Side effects · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Salivary flow rate (stimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Chinese medicine led to higher salivary flow rate (stimulated) compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Xerostomia (grade >= 2, 0-4 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Palifermin showed no clear difference in xerostomia (grade >= 2, 0-4 scale) compared with placebo (low certainty).
1 finding from 1 review